Illumina technology can advance immunology research by helping elucidate immune cell function and signaling. The causes of complex autoimmune diseases (such as lupus, rheumatoid arthritis, and multiple sclerosis) and other immunological disorders are still poorly understood.
Array and next-generation sequencing (NGS) solutions from Illumina can help immunology researchers gain insight into potential autoimmune disease mechanisms, the immune repertoire, and the functional consequences of immune-related genetic variation. Illumina NGS provides the quality, throughput, and read lengths required by the research community to map the immune response at high resolution.
NGS is proving to be a powerful tool to map the vast repertoire of immune cells that are capable of recognizing a seemingly boundless array of targets.1 Repertoire sequencing has enabled researchers to identify unique receptor variants found in individuals with susceptibility to autoimmune disorders, hematological malignancies, and other diseases.2
RNA-Seq and HLA typing are increasing the power and efficiency of a target discovery platform.Read More
Researchers query the genome with NGS and perform high-throughput genotyping to identify novel risk loci for immune-mediated disease.Read More
Researchers unravel disease mechanisms by sequencing the TCR repertoire as well as mitochondrial DNA and piwi-interacting RNA.Read More
AmpliSeq for Illumina Immune Repertoire Plus, TCR beta Panel: Investigate T cell diversity and clonal expansion by sequencing T cell receptor (TCR) beta chain rearrangements.
AmpliSeq for Illumina TCR beta-SR (Short Read) Panel: FFPE-compatible panel for measuring T cell diversity and clonal expansion in tumor samples by sequencing TCR beta chain rearrangements.
AmpliSeq for Illumina Immune Response Panel: Targeted RNA expression panel investigating 395 genes involved in tumor-immune system interactions.
Infinium Immunoarray: Evaluate autoimmune disorder and immune function–associated genetic variants on a single microarray.
NGS can help researchers identify mutations that enable tumors to evade the immune response, as well as neoantigens that can boost T cell-mediated immunity.